Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.

From Your Site Articles

Eli Lilly is looking to Houston for a new facility. Getty Images

Pharmaceutical giant plans $5.9B Houston facility and more news to know

Trending News

Editor's note: It's time to look back at the top Houston innovation news from the second half of May 2025. From exciting VC raises to major manufacturing facilities in the works, here are the most-read InnovationMap stories from May 16-30.

1. Pharmaceutical giant looks to bring $5.9 billion facility to Houston

Eli Lilly is looking to build an active pharmaceutical ingredient manufacturing facility at Generation Park. Rendering courtesy of McCord

Pharmaceutical company Eli Lilly and Company is looking to build a $5.9 billion active pharmaceutical ingredient (API) manufacturing facility in Houston, according to a recent filing with the state of Texas.

The proposal states that the project plans to employ 604 full-time direct employees at the site upon ramp-up completion. Construction is projected to begin in 2026, with a completion target of 2030 and commercial operations beginning in 2031. Continue reading.

2. Houston VC firm closes $21M fund for underrepresented founders

Zach Ellis, founder and general partner of South Loop Ventures, which recently closed its debut fund. Photo via LinkedIn

Houston-based South Loop Ventures recently closed its debut fund for more than $21 million, led by investments from Rice Management Company and Chevron Technology Ventures.

The funds will go toward teams with at least one underrepresented founder of color working in the energy, health, space, sports and fintech sectors. Additional investments came from The Great Commission Foundation of the Episcopal Diocese of Texas, Texas CapitalBank and others organizations. Continue reading.

3. Houston-founded startup raises $1.2M and moves headquarters to Detroit

ChurchSpace, founded in Houston by Day Edwards and Emmanuel Brown, is moving to Detroit. Photo courtesy ChurchSpace.

Houston-founded ChurchSpace, known as the Airbnb for churches, has formed an official partnership with the City of Detroit and will relocate its headquarters.

The announcements come as the company successfully closed a $1.2 million oversubscribed funding round. The round was led by California-based Black Ops Ventures, with participation from Michigan Rise and Dug Song of Minor Capital, who is also the founder of the Song Foundation, another Michigan-based organization. Continue reading.

4. Houston aerospace co. soars with first U.S. test flight of hypersonic engine

Venus Aerospace successfully completed the flight test of its hypersonic engine, the first of an American-developed engine of its kind. Photo courtesy Venus Aerospace

Houston-based Venus Aerospace successfully completed the first U.S. flight test of its proprietary engine at a demonstration at Spaceport America in New Mexico.

Venus’ next-generation rotating detonation rocket engine (RDRE) is supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA and aims to enable vehicles to travel four to six times the speed of sound from a conventional runway. The recent flight test was the first of an American-developed engine of its kind. Continue reading.

5. Houston regenerative medicine company expands lab for future trials

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. With its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research. Continue reading.

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

Houston regenerative medicine company expands lab for future trials

new digs

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. Fibroblasts are the primary variety of cells that compose connective tissue. FibroBiologics has found in studies that fibroblasts can be even more powerful than stem cells when it comes to both regeneration and immune modulation, meaning they could be a more versatile way forward in those fields.

In 2023, FibroBiologics moved into new lab space in the UH Technology Bridge. Now, with its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research.

The new space includes more than 10,000 square feet of space devoted to both labs and offices. The location is large enough to also house manufacturing drug product candidates that will be used in upcoming trials. Additionally, the company reports that it plans to hire additional researchers to help staff the facility.

“This expansion marks a transformative step forward for our company and our mission,” Pete O’Heeron, FibroBiologics founder and CEO, said in a news release. “By significantly increasing the size of our lab, we are creating the space and infrastructure needed to foster greater innovation and accelerate scientific breakthroughs.”

The streamlined, in-house manufacturing process will reduce the company’s reliance on external partners and make the supply chain simpler, O’Heeron added in the release.

Hamid Khoja, the chief scientific officer for FibroBiologics, also chimed in.

“To date, our progress in developing potentially transformative therapeutic candidates for chronic diseases using fibroblasts has been remarkable,” he added in the release. “This new laboratory facility will enable further expansion and acceleration of our research and development efforts. Additionally, the expansive new space will enable us to bring in-house currently outsourced projects, expand our science team and further contribute to the increased efficiency of our R&D efforts.”

This news arrives shortly after a milestone for the company in its research about neurodegenerative disease. Last month, fibroblast treatments in an animal model study demonstrated a notable regeneration of the myelin sheath, the layer that insulates nerves and is worn down by disease.

“Confirming remyelination in a second validated animal model is an important step in our research and development efforts, offering fresh hope for patients with demyelinating diseases, including multiple sclerosis,” O’Heeron added in a separate release. “These findings advance our mission to develop transformative fibroblast-based therapies that address the root causes of chronic disease, not just their symptoms, and reflect our dedication to pushing the frontiers of regenerative medicine."

The event spotlighted the organization’s strides in regenerative medicine, fueling advancements in adult stem cell therapies for conditions often deemed incurable, such as Parkinson’s Disease, multiple sclerosis, and spinal cord injuries. Photo via Si Vo

Houston gala attendees prescribe $1M for groundbreaking stem cell research

breaking boundaries

There’s a new gala in H-town, folks, and it made its grand, sold-out debut thanks to a power couple known for believing that the sky's the limit when it comes to local philanthropy. Chairs Jessica Rossman and Gordon Bethune piloted the inaugural Hope Biosciences Research Foundation (HBRF) fundraiser on October 26 at the Post Oak Hotel in Uptown Houston.

The evening offered patrons a deeper look into the group’s pioneering work, led by co-founders Donna and Daniel Chang. More than 400 supporters — many of whom have witnessed the impact of HBRF’s clinical trials on their health and the lives of loved ones — were enticed to partake in the event by a host committee helmed by Donae, Bella, and Rob Chramosta.

Sherry Diers and David Gonzales, hosts of the foundation’s Hopeful News Network podcast, shared heartfelt stories from their hands-on experiences with HBRF patients. In a touching moment, high school senior Bella Chramosta recounted her own health journey before announcing the inaugural HBRF Luminary Award recipients — Ema Suljkanovic, Rachel Phillips, and Alayna Nunez. The three Kingwood High School students had raised $1,400 for the foundation, and Houston icon Jim “Mattress Mack” McIngvale proudly presented the award.

HBRF offered a Hope-inspired jewelry pull, sponsored by Thomas Markle Jewelers. Each silver necklace entry doubled as a ticket for a chance to win a diamond version of the necklace — 2.27 carats in 18kt white gold, valued at $7,500. The winning ticket, drawn by Sarah and Phillip Markle, brought cheers from those who purchased necklaces throughout the evening. Guests enjoyed a silent auction chaired by Cathy Jackson, featuring everything from health and beauty experiences to travel packages like golfing at St. Andrews and fishing in Cabo.

Gala-goers were treated to a meaningful musical performance by Faith and Jon Hartlage. Upon departure, each guest received a gift from Hope Biosciences, LLC — a tube of Wondercell gel, an anti-aging product made from stem cell byproducts, as a reminder of the foundation’s impact both inside and outside the lab.

Seen on the scene were Ginger and Dick Hite, Maria and Omar Alaoui, Roslyn Bazzelle Mitchell, Cheryl Byington, Gracie and Bob Cavnar, Anna Dean, Karen and Peter Remington, Dr. Romy Dell’Ario, Jan Duncan, Nene Foxhall, Mandy Kao, Stacey Lindseth, Linda McIngvale, Beth Muecke, Patti Murphy, Jennifer Pinkerton, Rachel and Tom Regan, Dallas Rowdan, Ally Shell, Natalie Wall, Christina Zhou, Tama Lundquist and Dr. Peter Farrell, Stephanie and Gary Loveless, Azeemeh Zaheer, Chris Perry, Gregg Harrison, and Dr. Roland Maldonado.

------

This article originally ran on CultureMap.

FibroBiologics will IPO this week. Photo via Getty Images

Houston regenerative medicine company to IPO, move toward more human trials

ready to list

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Planned KBR spinoff scores $1B NOAA deal for extreme weather forecasting

weather watch

Amid a major spinoff, Houston-based KBR's Mission Technology Solutions business has been awarded a five-year contract for up to $1.1 billion from NOAA’s National Weather Service to help predict and combat extreme weather conditions.

Under the follow-on Commercial Data Program National Mesonet Program (CDP NMP) contract, KBR will provide weather and observational data from commercial stations, university and research campuses, and other non-federal providers nationwide. The information collected will assist in predicting severe temperatures and high-impact weather conditions like extreme storms.

"This award underscores KBR's proven track record of delivering vital data that strengthens national forecasting capabilities," Todd May, KBR’s senior vice president of Mission Technology Solutions, said in a news release.

According to a separate release from NOAA, the contract expands upon KBR's existing relationship with the agency. KBR will work with about 70 private industry partners on services such as data recording, collection, aggregation and processing, and will lead the CDP NMP's "network of networks."

“NOAA gathers environmental information from a wide variety of sources, and a growing list of private industry partners have joined our agency to collect this vital data,” Ken Graham, director of NOAA’s National Weather Service, said in the release. “This agreement streamlines the process that turns raw data into the gold-standard forecasts that Americans depend on.”

KBR will utilize its Speed to Mission ImpactSM technology for the project to supply data from across regions, measurement types, and system configurations. Both KBR and NOAA say the expanded data collection contract will help the agency create more accurate and timely forecasts, particularly for severe weather and extreme events, while also creating a path for new weather-observation technologies.

KBR has supported the CDP NMP for more than 9 years. The program will be managed in Greenbelt, Maryland.

"We're driving expanded integration of commercial sensor and data sources into this platform and are honored to know our work helps forecasters give their communities earlier warnings and more time to prepare for dangerous weather,” May added in a release.

KBR’s Mission Technology Solutions business will be rebranded as Trinzic after its planned spin-off, the company announced last month. The spin-off is expected to close in January 2027.

Trinzic will work as an independent, publicly traded company focused on technology and engineering services for the space and national security sector. KBR will remain a separate publicly traded company that will focus on sustainable technology and services to support the energy transition.

This is the salary required to live comfortably in Texas in 2026

Money Matters

A new national report looking at the income it takes to live comfortably in each of the 50 states has revealed Texans need to earn slightly less now than a year ago.

SmartAsset analyzed what a single individual, as well as family of four, must earn to cover minimum basic needs adjusted using the 50/30/20 budgeting rule. The resulting estimate represents the annual, pre-tax income needed to live comfortably in every U.S. state.

A single, full-time worker needs to make $90,563 to live comfortably in the Lone Star State, the report found, which is down a meager 0.2 percent from last year ($90,771).

Under the 50/30/20 budgeting strategy, that means a single Texas earner would have $45,282 to spend on necessities like housing and utilities, $27,169 for discretionary spending, and $18,113 for emergencies or retirement savings.

Texas ranked 34th nationally in SmartAsset's list of states with the highest income needed for a single adult to live "in sustainable comfort" in 2026. Only five other states — Tennessee, Maryland, Louisiana, North Carolina, and Mississippi — saw a decline in the income needed to live comfortably this year.

For a family of four to live comfortably in Texas, income requirements change significantly, according to the findings. To support a two-child household, a family needs $203,424 in combined total household income to be considered financially stable. This is down slightly from 2025, when SmartAsset reported a family of four in needed $204,922 to live comfortably in Texas.

This is a comfortable lifestyle for a family of four in Texas, according to the report:

$101,712 dedicated to necessities and living expenses
$61,027 dedicated to discretionary spending
$40,685 dedicated to emergencies, savings, or debt repaymen

According to the report, a family of four now needs to make at least $200,000 to live comfortably in 40 U.S. states, a figure that is far out of reach for many American families.

"As housing, grocery, transportation and other essential costs pressure household budgets, earning a six-figure salary no longer guarantees financial comfort in much of the U.S.," the report said. "A single adult now needs at least $80,000 a year to live comfortably in every state, while the threshold exceeds $100,000 in nearly half of states. For a family of four, the income needed to live comfortably is as much as $329,000."

Still, earning the minimum income to live comfortably in Texas doesn't guarantee financial stability in the Lone Star State's major cities. Earlier this year, SmartAsset determined single residents in Houston need to make about $90,000 to qualify as financially stable, while families of four need around $205,000.

---

This article originally appeared on CultureMap.com.

Texas is the 7th hardest working state in America for 2026, says report

Labor Day Report

Texans pride themselves on being industrious, and a new report has confirmed Texas as one of the 10 most hardworking states in America in 2026.

The Lone Star State claimed the No. 7 spot this year in a slight dip from its 2025 ranking, where it appeared in the top five. Texas last ranked 7th in 2024, but the state has consistently appeared among the top 10 for nearly a decade.

WalletHub determined the rankings after analyzing 10 "direct" and "indirect" work factors across all 50 states, and then graded each metric on a 100-point scale, where a score of 100 signified the "hardest working." Analysts then examined each state’s weighted average across all metrics to calculate its overall score and used the resulting scores to rank-order the states.

There was only a 10.32-point difference between Texas and South Dakota, who claimed the top spot as America's hardest working state in 2026 with a score of 64.59 out of a possible 100 points.

Texas ranked 6th nationally in the "direct" work factors category, which examined the following six metrics:

The state's average workweek hours.
Employment rates.
The share of households where no adults work.
The share of workers leaving vacation time unused.
The share of "engaged" workers — those that are "involved in, enthusiastic about, and committed to their work and workplace," as defined by Gallup.
The rate of "idle youth" — individuals aged 18-24 who are not currently enrolled in school, not working, and have no degree beyond a high school diploma or GED.

Texas ties with Louisiana for the second highest average workweek hours nationwide, with Alaska topping the list with the No. 1 longest workweeks in America. Alaska is the only state where workers clock in more than 40 hours per week at their jobs, with WalletHub reporting Alaskans work 41.4 hours on average weekly.

In the "indirect" work factors category — which encompassed workers' average commute times, the share of workers with multiple jobs, annual volunteer hours per resident, and the average leisure time spent per day — Texas ranked 36th nationwide.

Here's how WalletHub ranked Texas in three individual metrics:

No. 10 – Average commute times
No. 20 – Average leisure time spent per day
No. 30 – Employment rates

According to the World Economic Forum, Americans clock in about 1,800 hours at work per year on average, which is 468 more hours per year than workers in Germany. And many are leaving vacation time on the table, WalletHub says.

"Even when given the chance to take time off, many Americans won’t, as nearly half of workers don't expect to use all of their allotted vacation days," the report said. "It is possible to work hard without overdoing it, though. Hard work is key to success, and the residents of some states understand that better than others."

The top 10 hardest working states in America in 2026 are:

No. 1 – South Dakota
No. 2 – North Dakota
No. 3 – Alaska
No. 4 – Hawaii
No. 5 – Wyoming
No. 6 – Nebraska
No. 7 – Texas
No. 8 – New Hampshire
No. 9 – Tennessee
No. 10 – Georgia

---